HOUSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) (Salarius or the Company) announces that on October 10, 2025 the Company received notice from the Nasdaq Stock Market LLC (Nasdaq) that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), the Equity Standard Requirement. This follows the Company's announcement on September 9, 2025 that it had regained compliance with Nasdaq Listing Rule 5550(a)(2), the Minimum Bid Price Requirement."Salarius is now fully comp ...